Estudio de coste eficacia en el manejo de la degeneración macular asociada a edad en la práctica clínica real con renibizumab

Abstract

Age-related macular degeneration is a challenge for modern ophthalmology, since in recent years has evolved from the inability to treat, to the race to improve both the visual results as the associated costs and burdens of care services that have changed retinal departaments. One of the determining factors in this change were antiangiogenic drugs, which have improved prognosis of patients but have complicated the efforts of our units. ARMD is a degenerative disease that usually starts in the innermost layer of the choroid, as drusen, and from age 40. These alterations are growing in magnitude causing the macular function is affected to a complete loss, either in its evolution towards atrophic or to the wet form. ARMD is the leading cause of non-reversible blindness in people over 60 years: more common in Caucasians. Studies of the 90s and the first decade of the 2000s are consistent in the distribution of the disease, the most important risk factor for ARMD is age; increased risk to older, being up to 16 times higher in the group of more than 75 years old, compared to over 65. Bilateralisation is also a key factor in the management of patients, for up to 70-83% of cases 5 years suffer CNV in the fellow eye. ARMD is one of the most prevalent diseases causing blindness, together with cataracts, glaucoma and diabetic retinopathy as the European Forum Against Blindness says...